- Global Pharma News & Resources

Sirolimus Market 2020 Size, Demand, Share, Regional Insight Growing Volume, Product & Service, Technology, Indication And End-User by 2026

Global Sirolimus Market

Sirolimus is a macrolide compound, which is also known as rapamycin.  It is a potent immunosuppressant and boasts both antifungal and antineoplastic properties. It works by weakening the immune system, and helps your body to accept the new organ, so in this manner it helps in preventing rejection of any organs after transplant. Sirolimus is also used to coat coronary stents, and prophylaxis of organ transplant rejection in patients receiving renal transplants, and for treating Lymphangioleiomyomatosis (lung disease).

Request to download and view Sample Report:

Global Sirolimus Market Dynamics

Approvals for generic versions of Rapamune (a branded sirolimus formulation) for preventing organ transplant rejection is expected to drive the global sirolimus market growth. For instance, in January 2019, Novitium Pharma LLC received the final approval for its abbreviated new drug application (ANDA) from the U.S. FDA to market a generic version of an oral solution of Rapamune 1mg/ml manufactured by PF Prism CV. In October 2014, Dr. Reddys Laboratories Ltd., received the final approval for its abbreviated new drug application (ANDA) from the U.S, FDA to market a generic version of Rapamune tablet dosage (1mg). Thus, approvals of sirolimus products by regulatory authorities to manage (or prevent) organ transplant rejection is expected to drive growth of the global sirolimus market.

Thus, factors such as rising incidence of kidney diseases has led to an upsurge in the number of kidney transplants. Furthermore, growing prevalence of lifestyle-related disorders, improvement of healthcare infrastructure due to increasing healthcare spending is expected to support global sirolimus market growth over the forecast period. According to the National Kidney Foundation, in 2014, around 17,107 kidney transplants took place in the U.S., among which, 5,537 kidneys were from living donors, and 11,570 kidneys were from deceased donors.

Moreover, rising incidence of the Alagille syndrome, Cystinosis, Glomerulonephritis, Nephrotic syndrome, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), Interstitial nephritis, and others is expected to result in increasing demand for transplants. Major market players are engaged in research and development activities and product launches in order to introduce optimized dosage forms. For instance, in 2014, Rapamune, a formulation developed by Pfizer, lost its exclusivity as an immunosuppressant for kidney transplant rejection management in the U.S. However, in 2015, Rapamune became the first U.S. FDA-approved drug for treating Lymphangioleiomyomatosis (LAM) which is a rare progressive lung disease. These factors are therefore anticipated to support global sirolimus market growth over the forecast timeline.

Tailored Information as per niche requirement:

Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Sirolimus Market – Regional Insights

North America is anticipated to dominate the global sirolimus market due to an increasing number of product approvals for preventing organ transplant rejection. For instance, one of the major leading companies, Pfizer Inc., has carried out various clinical trial studies on sirolimus 1mg/2mg dose for different treatments such as graft rejection, kidney transplant, renal allograft recipients, and renal transplants which has successfully completed phase IV in 2013.

Furthermore, growing demand for kidney transplants is expected to propel growth of the global sirolimus market growth over the forecast period. In 2014, the National Kidney Foundation, U.S., reported that every month approximately 3,000 patients were added to the kidney transplant waiting list, and an estimated 13 people died each day while waiting for a life-saving kidney transplant.

Global Sirolimus Market Restraints

Some of the factors restraining the global sirolimus market growth are the side effects associated with the use of sirolimus, such as increased susceptibility to infection, malignancy, hypertriglyceridemia, hypercholesterolemia, angioedema, and proteinuria. Administering sirolimus to patients undergoing liver and lung transplants is generally avoided, owing to these side effects.

Key Market Players

Some of the most prominent companies operating in the global sirolimus market include Pfizer Inc., Actiza, Zydus Cadila Healthcare Ltd., Inc., Greenstone LLC, Biocon, Livzon NNR, and Intas Pharmaceuticals Ltd.

To understand Research Methodology, please click

Market Taxonomy

By Strength,

  • 0.5mg
  • 1mg
  • 2mg
  • 1mg/mL

By Route of Administration,

  • Oral
  • Intravenous

 By Distribution Channel,

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region,

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 13-Jan-2021